Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: An analysis of 203 consecutively treated patients

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Figlin, Robert ^a,b   Gitlitz, Barbara ^a   Franklin, John ^b   Dorey, Frederick ^b   Moldawer, Nancy ^a   Rausch, Jeffrey ^b   Dekernion, Jean ^b   Belldegrun, Arie ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Interleukin 2; Renal cell carcinoma; UCLA Kidney Cancer Database

Indexed keywords

FLOXURIDINE; FLUOROURACIL; INTERLEUKIN 2; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; BOLUS INJECTION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL TRANSFORMATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0031431311     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bassil B, Dosoretz DE, Prout GR Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J Urol 1985; 134:450-454.
2. Golimbu M, Joshi P, Sperber A et al. Renal cell carcinoma: survival and prognostic factors. Urology 1986;27:291-301.
3. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urology 1986;136:376-379.
4. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48:7310-7313.
5. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13: 688-696.
6. Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol 1987;14:36-42.
7. Figlin RA, Pierce WC, Kaboo R et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urology 1997;158:740-745.
8. Figlin RA, Belldegrun A, Moldawer N et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2a: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992;10:414-421.
9. Yang JC, Topalian SL, Parkinson D et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994;12:1572-1576.
10. Giditz BJ, Dolan N, Pierce W et al. Fluoropyrimidines plus interleukin-2 and interferon-alpha in the treatment of metastatic renal cell carcinoma: the UCLA kidney cancer program. Proceedings of ASCO 1996;15:630a.
11. Fisher RI, Rosenberg SA, Sznol M et al. High-dose proleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 1997;3 [suppl 1]:S70-S72.
12. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell carcinoma using high-dose bolus interleukin 2. JAMA 1994;271:907-913.
13. Montie JE, Stewart BH, Straffon RA et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urology 1977;117:272-275.
14. deKernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urology 1978;120:148-152.